Toxicological evaluation of insulin glargine İnsülin glarjin kullaniminin toksikolojik açidan deǧerlendirilmesi

ERKEKOĞLU Ü. P., Giray B., Şahin G.

Hacettepe University Journal of the Faculty of Pharmacy, vol.30, no.2, pp.187-204, 2010 (Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 30 Issue: 2
  • Publication Date: 2010
  • Journal Name: Hacettepe University Journal of the Faculty of Pharmacy
  • Journal Indexes: Scopus
  • Page Numbers: pp.187-204
  • Keywords: Cancer, Diabetes, Insulin, Insulin analogues, Insulin glargine and its toxicology
  • Lokman Hekim University Affiliated: No


Diabetes mellitus is a disease in which a person has a high bloodglucose level as a result of the body either not producing enough insulin(Type 1), or because body cells do not properly respond to the insulinthat is produced (Type 2). Insulin is a hormone produced in the pancreaswhich enables body cells to absorb glucose, to turn into energy. If thebody cells do not absorb the glucose, hyperglycemia leads to various potentialmedical complications. Obesity, sedentary life style, aging populationand mortality decreases of geriatric population cause increases inthe incidence of diabetes. Insulin analogues are altered forms of insulin,different from any occurring in nature and they are anti-diabeticsused for supplying glycemic control. Insulin glargine (C267H408N72O77S6) is a human insulin analogue produced by recombinant DNA technology.It is a long-acting analogue with a duration of action of 18 to 26 hoursand with a "peakless" profile of effect-time curve. This review will focuson the toxicological profile of insulin glargine: pharmaco/toxico-kineticsand dynamics, side effects, drug interactions and its relationship withcancer due to evidences related to the subject.